SCHEMBL14018342

SCHEMBL14018342

C(=C(c1ccccc1)c1ccccc1)c1ccc(N(c2ccccc2)c2ccc(N(c3ccccc3)c3ccc(-c4ccc(N(c5ccccc5)c5ccc(N(c6ccccc6)c6ccc(C=C(c7ccccc7)c7ccccc7)cc6)cc5)cc4)cc3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.50
CYP11B2 P19099 2/20 0.50
PTGS2 P35354 5/20 0.47
ESR1 P03372 2/20 0.47
ESR2 Q92731 1/20 0.42
TP53 P04637 1/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
CYP2D6 P10635 2/20 0.40
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6140178 1.00 CYP19A1 (0.50) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL14018366 1.00 CYP19A1 (0.50) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL2328313 1.00 CYP19A1 (0.50) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL14018372 1.00 CYP19A1 (0.50) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL14018344 1.00 CYP19A1 (0.50) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL9971850 1.00 CYP19A1 (0.50) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL6140079 1.00 CYP19A1 (0.50) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL12533806 0.98 CYP19A1 (0.49) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL6140633 0.98 CYP19A1 (0.52) CYP19A1CYP11B2PTGS2ESR1ESR2
SCHEMBL14018373 0.97 ESR1 (0.49) CYP19A1CYP11B2PTGS2ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080241591-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND PHENYLENEDIAMINE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-10-02 US disclosed
US-20080241591-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND PHENYLENEDIAMINE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-10-02 US disclosed
US-7399537-B2 Organic electroluminescence device and phenylenediamine derivative IDEMITSU KOSAN CO., LTD. (JP) 2008-07-15 US disclosed
US-7399537-B2 Organic electroluminescence device and phenylenediamine derivative IDEMITSU KOSAN CO., LTD. (JP) 2008-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241591-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND PHENYLENEDIAMINE DERIVATIVE MAL2, L1CAM, EPCAM CYP19A1 2533/4885CYP11B2 2458/4885PTGS2 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.